Cell Processing CDMO Business to be Succeeded by a Subsidiary S-RACMO

Nov. 2, 2026

Sumitomo Chemical hereby announces that on November 2, 2026, its subsidiary, S-RACMO Co., Ltd. (“S-RACMO”), executed a Master Agreement with Takara Bio Inc. (“Takara Bio”). This will serve as the definitive agreement for S-RACMO’s succession of Takara Bio’s GMP-compliant cell processing CDMO business.

For more information, please refer to the press release published on November 2, 2026, by S-RACMO and Takara Bio.
https://www.takara-bio.com/en/news/-news_261102E/main/0/teaserItems1/01111113/linkList/00/link/TB26-1045..pdf

Sumitomo Chemical has positioned the regenerative medicine and cell therapy fields as one of the medium- to long-term growth pillars of its Advanced Medical Solutions Sector and is advancing initiatives across the Group from research and development through commercialization. Through this agreement, S-RACMO will take over personnel, assets, contract projects, and other items, and will combine the technologies and know-how in cellular immunotherapies cultivated by Takara Bio with S-RACMO’s experience in the manufacturing of regenerative medicine and cell therapy products, thereby strengthening its contract manufacturing capabilities and business foundation. Sumitomo Chemical considers this transaction to be an important initiative toward expanding its regenerative medicine and cell therapy business.

The Sumitomo Chemical Group will continue to promote the expansion of its regenerative medicine and cell therapy business as part of its healthcare solutions, including advanced medical care, and contribute to solving societal issues.

Contact

Sumitomo Chemical Co., Ltd.
Corporate Communications Dept.
https://www.sumitomo-chem.co.jp/english/contact/public/